OptimizeRx Continues COVID-19 Webinar Series, Addressing the Rapid Adoption of Telehealth
2020年4月17日 - 5:01AM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, will
continue its webinar series on COVID-19 next week to address the
rapid adoption of telehealth with industry veterans from Carla
Smith Health and Genius Rx.
This will be the sixth in a series of webinars
OptimizeRx has been hosting to facilitate industry collaboration
across healthcare verticals in response to COVID-19. The
conversation around telehealth brings together thought leaders with
deep industry relationships who have driven innovation in the
healthcare space through the implementation of disruptive
technologies and strategic collaboration.
The panel will be moderated by OptimizeRx
president, Miriam Paramore. She will be joined by Carla Smith, CEO
of Carla Smith Health. Smith recently spearheaded American
Telemedicine Association’s Quick-Start Guide to Telehealth, a
resource for providers looking to quickly establish telehealth
services during a public health crisis. Smith previously served as
EVP of HIMSS for 17 years, leading U.S. and Canada strategy. She
was named one of the Most Powerful Women Thought Leaders in Health
IT and Most Influential Woman in Health IT several years in a row
by Health Data Management.
The panel will also include Randy Parker,
founder & CEO of Genius Rx, who has 30 years of experience
starting and building successful, disruptive, consumer-focused
companies including MDLIVE.
Topic: Learning
Together—The Rapid Adoption of Telehealth During
COVID-19. Will it Stick? In the face of social distancing
to prevent further spread of the coronavirus, telehealth has
emerged as the safest and most viable way to ensure patients have
access to medical consults and care.
While telehealth is not new, it is suddenly
experiencing unprecedented demand and easing of regulations because
of the coronavirus crisis. Will this lead to a more permanent use
of telehealth? Will broader telehealth initiatives persist after
the pandemic subsides? The discussion will address the intricacies
and opportunities of this extraordinary moment for telehealth, the
growing importance of virtual care and its place in telehealth, and
what these changes mean for the healthcare industry as a whole.
Date: Wednesday, April
22Time: 1:00 p.m. ET
The webinar is open and free to anyone
interested in participating in a practical conversation with
industry leaders. OptimizeRx hosts these discussions to explore the
transformational changes occurring in healthcare, and to connect
the various stakeholders in a way that drives innovation,
collaboration and education.
Register today at
www.optimizerx.com/webinars.
For more information about OptimizeRx’s webinar
sessions, contact media relations at (754) 245-7070 or
malejandra@optimizerx.com.
About OptimizeRxOptimizeRx®
(NASDAQ: OPRX), a digital health company, connects pharmaceutical
companies to patients and providers, offering greater
affordability, adherence and brand awareness at the point-of-care.
As the nation’s largest digital platform connecting life sciences
to the point-of-care, OptimizeRx provides a direct channel for
pharma companies, payers, medtech, and medical associations to
communicate with healthcare providers right within their workflow
and also directly to patients.
The cloud-based solution supports patient
adherence to medications and better healthcare outcomes with
real-time access to financial assistance, prior authorization,
education and critical clinical information. OptimizeRx provides
more than half of the ambulatory patient market with access to
these benefits through leading EHR platforms like Allscripts,
Amazing Charts and Quest, and directly via its mobile
communications platform and digital therapeutics SaaS platform.
For more information, follow the company on
Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward
Looking StatementsThis press release contains
forward-looking statements within the definition of Section 27A of
the Securities Act of 1933, as amended, and such as in section 21E
of the Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker,
CFOTel (248) 651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira
Alejandra, Media Relations ManagerTel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact Ron
Both, CMATel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024